Drug Profile
SYM 2229
Alternative Names: SYM-2229Latest Information Update: 06 Nov 2006
Price :
$50
*
At a glance
- Originator Annovis
- Class
- Mechanism of Action AMPA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 06 Nov 2006 Discontinued - Preclinical for Epilepsy in USA (unspecified route)
- 13 Jan 2003 No development reported - Preclinical for Epilepsy in USA (unspecified route)
- 28 Nov 2000 Preclinical development for Epilepsy in USA (Unknown route)